Activation and Regulation of the Understudied Kinome Using MIB/MS Technology
Activation and Regulation of the Understudied Kinome Using MIB/MS Technology
批准号:
9120936
负责人:
GARY L. JOHNSON
金额:
$39.51万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2018-04-30
关键词:
AddressAffinityAntibodiesBindingBiologicalBiological AssayBiologyBone MarrowBrainBreast Cancer geneCell LineCell physiologyCellsChemicalsChromatinClinicalCoupledCytoskeletonDDR1 geneDDR2 geneDNA DamageDevelopmentDiseaseERBB2 geneEnzymesEpigenetic ProcessFutureGene FusionGenetic ScreeningGlioblastomaGoalsHealthHeartHistocompatibility TestingHumanHuman Cell LineInformaticsKidneyKnowledgeLipidsLiverLungMAP2K1 geneMAPK1 geneMAPK3 geneMalignant neoplasm of lungMalignant neoplasm of pancreasMass Spectrum AnalysisMeasurementMeasuresMetabolicMethodsMusMutationNodalNormal tissue morphologyPancreasPatientsPharmaceutical PreparationsPhosphorylationPhosphotransferasesPrincipal Component AnalysisProtein IsoformsProtein KinaseProtein Kinase InhibitorsProteinsPublished CommentRNA InterferenceRNA interference screenReagentReceptor Protein-Tyrosine KinasesRegulationRenal Cell CarcinomaResearchRunningSepharoseSeriesSignal TransductionSystemTechnologyTissuesTumor Cell LineTumor TissueXenograft procedurebasebcr-abl Fusion Proteinscancer typedark matterdrug discoveryhigh throughput technologyhuman diseasein vivoinhibitor/antagonistkinase inhibitorknock-downleukemiamelanomanovel strategiesoverexpressionpreferenceprotein kinase inhibitorresponsetranscriptome sequencingtumor
中文摘要
描述:一种新的方法已经实施,以研究蛋白激酶的激活状态“整体”。我们的方法允许从细胞系、组织和肿瘤中分离和分析蛋白激酶,使用Multiplexed Inhibitor Beads (MIBs)进行单质谱分析。MIBs是由磷酸酶珠与共价固定、连接剂适应、激酶抑制剂的混合物组成。激酶捕获是可重复的,是一个功能
英文摘要
DESCRIPTION: A novel approach has been implemented to study the activation state of protein kinases "en masse". Our methods allow isolation and analysis of protein kinases from cell lines, tissues and tumors assayed in a single mass spectrometry run using Multiplexed Inhibitor Beads (MIBs). MIBs consist of mixtures of Sepharose beads with covalently immobilized, linker adapted, kinase inhibitors. Kinase capture is reproducible and is a function of
affinity of kinases for the different immobilized inhibitors as well as the activation state of the
kinase. The inhibitors we have synthesized for linker conjugation to Sepharose beads are primarily type 1 inhibitors that preferentially bind activated states of protein kinases. Extensive
characterization of the MIBs has demonstrated they have a strong preference for binding the active state of kinases and inactive kinases bind poorly. Using a layered bead composition for MIB columns, we are able to capture and identify more than 275 kinases in a single mass spectrometry run. Based on RNA-seq analysis, MIBs are capturing at least 75-80% of the expressed kinome from cell lines, tumors or normal tissues. Importantly, we have captured and characterized up to 275 kinases with as little as 500 mg protein from cell and tissue lysates. This level of sensitivity is essential for kinome analysis when tissue is limiting. Thus, MIB/MS provides an unparalleled scalable biology- based high throughput technology to assay the activation state of the kinome including "untargeted and understudied" kinases. There simply are few or no reagents for many of the "understudied" kinases, thereby limiting their study and MIB/MS overcomes these limitations. MIB/MS also detects activity changes in kinases for which reagents cannot distinguish closely related kinases (e.g., different activity states of MEK1 vs. MEK2 and ERK1 vs. ERK2, which are assessed together by anti-phospho-antibodies that cannot distinguish isoforms). Similarly, we can easily distinguish the regulation of related receptor tyrosine kinases (RTKs), such as DDR1 and DDR2, for which there are few reagents for study. The aims will define comprehensive kinome activation signatures that include poorly or uncharacterized kinases. Aims include: 1. Determine the activation state of the kinome using MIB/MS for a series of human cell lines spanning different cancer types, human and mouse tumors, and normal tissues of the mouse. 2. Determine the response of the kinome to perturbation of cellular physiology using specific chemical probes targeting protein and lipid kinases, cytoskeleton, metabolic regulators, DNA damage and epigenetic chromatin modifying enzymes. 3. Determine the consequence of RNAi knockdown of understudied kinases on the activation state of the kinome. The aims emphasize determining the activation state of understudied kinases and if specific understudied kinases function as part of a signature of kinase activation/inhibition in response to specific cellular perturbations. This analysis will defne the signaling networks and cellular functions for which the activity of understudied kinases are regulated and contribute to homeostatic control mechanisms. The goal is to identify and validate which current understudied kinases function as regulatory nodes within the kinome and warrant future chemical probe development.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/cmdc.201700663
发表时间:
2018-01-08
期刊:
ChemMedChem
影响因子:
3.4
作者:
[Asquith CRM, Laitinen T, Bennett JM, Godoi PH, East MP, Tizzard GJ, Graves LM, Johnson GL, Dornsife RE, Wells CI, Elkins JM, Willson TM, Zuercher WJ]
通讯作者:
Zuercher WJ
Illuminating Function of the Understudied Druggable Kinome
-
批准号:10251291
-
项目类别:
-
资助金额:$225.18万
-
财政年份:2017
-
负责人:GARY L. JOHNSON
-
依托单位:
Illuminating Function of the Understudied Druggable Kinome
-
批准号:9762097
-
项目类别:
-
资助金额:$226.6万
-
财政年份:2017
-
负责人:GARY L. JOHNSON
-
依托单位:
Illuminating Function of the Understudied Druggable Kinome
-
批准号:9453342
-
项目类别:
-
资助金额:$230.82万
-
财政年份:2017
-
负责人:GARY L. JOHNSON
-
依托单位:
Illuminating Function of the Understudied Druggable Kinome
-
批准号:10015261
-
项目类别:
-
资助金额:$225.92万
-
财政年份:2017
-
负责人:GARY L. JOHNSON
-
依托单位:
The adaptive kinome in pancreatic cancer
-
批准号:8859584
-
项目类别:
-
资助金额:$57.37万
-
财政年份:2015
-
负责人:GARY L. JOHNSON
-
依托单位:
Kinome Reprogramming in Response to Targeted Kinase Inhibitors
-
批准号:8457042
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2012
-
负责人:GARY L. JOHNSON
-
依托单位:
Kinome Reprogramming in Response to Targeted Kinase Inhibitors
-
批准号:8273335
-
项目类别:
-
资助金额:$27.89万
-
财政年份:2012
-
负责人:GARY L. JOHNSON
-
依托单位:
Kinome Reprogramming in Response to Targeted Kinase Inhibitors
-
批准号:8607578
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2012
-
负责人:GARY L. JOHNSON
-
依托单位:
Molecular Therapeutics
-
批准号:8340206
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2011
-
负责人:GARY L. JOHNSON
-
依托单位:
Regulation of Sequential Protein Kinase Pathways
-
批准号:8038148
-
项目类别:
-
资助金额:$10.14万
-
财政年份:2010
-
负责人:GARY L. JOHNSON
-
依托单位:
Receptor Interaction with GTP-Regulatory Proteins
-
批准号:7867340
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2009
-
负责人:GARY L. JOHNSON
-
依托单位:
Function of MEKK3 and its osmosensing scaffold protein
-
批准号:7889368
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2009
-
负责人:GARY L. JOHNSON
-
依托单位:
Defining Signal Network Plasticity
-
批准号:7498599
-
项目类别:
-
资助金额:$7.32万
-
财政年份:2008
-
负责人:GARY L. JOHNSON
-
依托单位:
EFFICACY OF COORDINATED SUPPORTIVE CARE IN GYNECOLOGIC ONCOLOGY PATIENTS
-
批准号:7608096
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2007
-
负责人:GARY L. JOHNSON
-
依托单位:
EFFICACY OF COORDINATED SUPPORTIVE CARE IN GYNECOLOGIC ONCOLOGY PATIENTS
-
批准号:7378108
-
项目类别:
-
资助金额:$2.08万
-
财政年份:2006
-
负责人:GARY L. JOHNSON
-
依托单位:
Inhibitor Screens for Five MAPK Kinase Kinases Important in Human Disease
-
批准号:7169344
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2006
-
负责人:GARY L. JOHNSON
-
依托单位:
EFFICACY OF COORDINATED SUPPORTIVE CARE IN GYNECOLOGIC ONCOLOGY PATIENTS
-
批准号:7203341
-
项目类别:
-
资助金额:$4.33万
-
财政年份:2005
-
负责人:GARY L. JOHNSON
-
依托单位:
UNC Center for Nanosensing the Stressome (RMI)
-
批准号:6930731
-
项目类别:
-
资助金额:$7.3万
-
财政年份:2004
-
负责人:GARY L. JOHNSON
-
依托单位:
Efficacy of Coordinated Supportive Care in Gynecologic Oncology Patients
-
批准号:6981289
-
项目类别:
-
资助金额:$2.78万
-
财政年份:2004
-
负责人:GARY L. JOHNSON
-
依托单位:
Function of MEKK3 and its osmosensing scaffold protein
-
批准号:8123425
-
项目类别:
-
资助金额:$31.14万
-
财政年份:2003
-
负责人:GARY L. JOHNSON
-
依托单位:
海外基金